Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of 68Ga-NOPO-c(RGDfK)

Molecular Pharmaceutics

Volumn 11, Issue 5, 2014, Pages 1687-1695

  Šimeček, Jakub ^a   Notni, Johannes ^a   Kapp, Tobias G ^b   Kessler, Horst ^b   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Munich Center for Integrated Protein Science   (Germany)

Author keywords

bifunctional chelators; gallium 68; hydrophilicity; integrins; positron emission tomography; RGD peptides

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4 BIS[METHYLENE(HYDROXYMETHYL)PHOSPHINIC ACID] 7 [METHYLENE (2 CARBOXYETHYL)PHOSPHINIC ACID]; ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE; CHELATING AGENT; CILENGITIDE; CUPRIC ION; GALLIUM; GALLIUM 68; GALLIUM(III); OCTANOL; PENTAPEPTIDE; PHOSPHINIC ACID DERIVATIVE; TETRAXETAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; WATER; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPLEX FORMATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG PURITY; DRUG SCREENING; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IMAGE RECONSTRUCTION; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; MELANOMA; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOCHEMISTRY; THIN LAYER CHROMATOGRAPHY; TUMOR GROWTH; TUMOR XENOGRAFT; URINARY EXCRETION; ANIMAL; CHEMISTRY; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; GALLIUM RADIOISOTOPES; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; MICE; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899827304     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5000746     Document Type: Article

References (51)

1. 3 integrin in cancer therapy and diagnosis Mol. Pharmaceutics 2012, 9, 2961-2973
2. 3 Angew. Chem., Int. Ed. 2013, 52, 11656-11659
3. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins in angiogenesis and lymphangiogenesis Nat. Rev. Cancer 2008, 8, 604-617
4. 3 for angiogenesis Science 1994, 264, 569-571
5. Barczyk, M.; Carracedo, S.; Gullberg, D. Integrins Cell Tissue Res. 2010, 339, 269-280
6. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins Science 1987, 238, 491-497
7. Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting Curr. Pharm. Des. 2006, 12, 2723-2747
8. Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature Drug Resist. Updates 2005, 8, 381-402
9. 3 antagonists J. Am. Chem. Soc. 1996, 118, 7461-7472
10. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett. 1991, 291, 50-54
11. 3 integrin antagonists J. Med. Chem. 1999, 42, 3033-3040
12. 3 selectivity of the anti-angiogenic drug Cilengitide by N-Methylation Angew. Chem., Int. Ed. 2011, 50, 9496-9500
13. Chatterjee, J.; Ovadia, O.; Zahn, G.; Marinelli, L.; Hoffman, A.; Gilon, C.; Kessler, H. Multiple N-methylation by a designed approach enhances receptor selectivity J. Med. Chem. 2007, 50, 5878-5881
14. 3-integrin expression in vivo Acc. Chem. Res. 2009, 42, 969-980
15. Gaertner, F. C.; Kessler, H.; Wester, H. J.; Schwaiger, M.; Beer, A. J. Radiolabelled RGD peptides for imaging and therapy Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S126-138
16. 3 expression Theranostics 2011, 1, 48-57
17. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates Bioconjugate Chem. 2004, 15, 61-69
18. 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 2001, 61, 1781-1785
19. 18F-galacto-RGD in cancer patients J. Nucl. Med. 2005, 46, 1333-1341
20. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin. Cancer Res. 2007, 13, 6610-6616
21. 3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET J. Nucl. Med. 2008, 49, 255-259
22. Wester, H. J. GMP - Shaping the future Nuklearmedizin 2012, 51, N1-4
23. 2 using a reference tissue model PloS One 2012, 7, e37506
24. 68Ga-Labeled c(RGDyK)- Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice J. Nucl. Med. 2008, 49, 830-836
25. 68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry Nuklearmedizin 2011, 50, 225-233
26. 3 integrin expression Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1507-1515
27. 3 integrin expression Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1303-1312
28. 3 Integrin Expression and Facile Radiosynthesis J. Nucl. Med. 2011, 52, 1276-1284
29. 68Ga-labelled peptides Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S31-S40
30. Notni, J. With Gallium-68 into a New Era? Nachr. Chem. 2012, 60, 645-649
31. 18F- Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process Nucl. Med. Biol. 2012, 39, 777-784
32. 68Ga generator eluates? ChemMedChem 2013, 8, 95-103
33. 3 Nucl. Med. Biol. 2013, 40, 33-41
34. 68Ga tracers for positron emission tomography Chem. - Eur. J. 2010, 16, 7174-7185
35. Notni, J.; Šimeček, J.; Hermann, P.; Wester, H. J. TRAP, a Powerful and Versatile Framework for Gallium-68 Radiopharmaceuticals Chem. - Eur. J. 2011, 17, 14718-14722
36. Šimeček, J.; Schulz, M.; Notni, J.; Plutnar, J.; Kubíček, V.; Havlíčková, J.; Hermann, P. Complexation of Metal Ions with TRAP (1,4,7-Triazacyclononane Phosphinic Acid) Ligands and 1,4,7-Triazacyclononane-1,4,7-triacetic Acid: Phosphinate-Containing Ligands as Unique Chelators for Trivalent Gallium Inorg. Chem. 2012, 51, 577-590
37. Notni, J.; Pohle, K.; Wester, H. J. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET EJNMMI Res. 2012, 2, 28
38. Šimeček, J.; Zemek, O.; Hermann, P.; Wester, H. J.; Notni, J. A monoreactive bifunctional triazacyclononane phosphinate chelator with high selectivity for gallium-68 ChemMedChem 2012, 7, 1375-1378
39. Šimeček, J.; Zemek, O.; Hermann, P.; Notni, J.; Wester, H. J. Tailored Gallium(III) Chelator NOPO: Synthesis, Characterization, Bioconjugation, and Application in Preclinical Ga-68-PET Imaging Mol. Pharmaceutics 2014, 10.1021/mp400642s
40. 68Ga-somatostatin antagonists: the chelate makes the difference J. Nucl. Med. 2011, 57, 1110-1118
41. 99mTc-labelled peptides Q. J. Nucl. Med. 2002, 46, 195-205
42. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12462-12467
43. Frank, A. O.; Otto, E.; Mas-Moruno, C.; Schiller, H. B.; Marinelli, L.; Cosconati, S.; Bochen, A.; Vossmeyer, D.; Zahn, G.; Stragies, R.; Novellino, E.; Kessler, H. Conformational control of integrin subtype selectivity in isoDGR peptide motifs: A biological switch Angew. Chem., Int. Ed. 2010, 49, 9278-9281
44. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation Anti-Cancer Agents Med. Chem. 2010, 10, 753-768
45. 111In via maleimido derivatives of DOTA and NODAGA Bioconjugate Chem. 2013, 24, 1102-1109
46. 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 481-492
47. 68Ga Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 478-485
48. Notni, J.; Šimeček, J.; Wester, H. J. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and application ChemMedChem 2014, 10.1002/cmdc.201400055
49. 68Ga]Oxo-DO3A-RGD for imaging αvβ3 integrin expression: synthesis, evaluation, and comparison Nucl. Med. Biol. 2013, 40, 65-72
50. 18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK) Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1469-1474
51. Šimeček, J.; Wester, H. J.; Notni, J. Copper-64 labelling of triazacyclononane-triphosphinate chelators Dalton Trans. 2012, 41, 13803-13806